What has colon cancer screening got to do with self-driving cars?
An excerpt from Scope Forward: The Future of Gastroenterology Is Now in Your Hands. Originally published on KevinMD.
NextServices partners with Gastrologix to launch GastroInfuse, a program to help GI practices develop infusion as an ancillary
We are excited to announce our new collaboration with Gastrologix in the launch of GastroInfuse, a new program that helps independent gastroenterology practices develop in-office infusion services.
What our clients said about our continued work during COVID-19. Even as we kept the dollars coming…
The best thing I like is the communication between us and the team…
PoopTech to AI and the microbiome: 10 Startups in Digital GI
March is National Colorectal Cancer Awareness month. While the GI world is busy educating patients about colonoscopy, the startup world is busy finding new ways to work with the gut.
Physician practice consolidation: It’s only just begun
Disruption has redefined health care in the past decade. For private practice physicians, the biggest disruptor has been consolidation.
Cologuard® expects to make over $1 billion in 2020. 16 Takeaways you must know from Exact Sciences Q4 2019 Earnings Call
Exact Sciences continues to be upbeat about Cologuard® and its overall business. The company expects revenues of $1.61-$1.645 billion in 2020 (Screening: $1.125-$1.15 billion and Precision Oncology: $485-$495 million). They are due to launch a liver cancer test in the second half of 2020.
What private equity has in store for GI in 2020
NextServices President and Co-founder Praveen Suthrum examined the current PE landscape in GI and offered insights into the future.